ACPH.BR实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (1 Jan 1970 @ 08:00):

Stats
今日成交量	761 376
平均成交量	402 314
市值	0.00
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.396
ATR14	$0 (0.00%)

Acacia Pharma Group PLC 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Acacia Pharma Group PLC 财务报表

Annual	2021
营收:	$1.16M
毛利润:	$868 000 (74.63 %)
EPS:	$-0.840

FY	2021
营收:	$1.16M
毛利润:	$868 000 (74.63 %)
EPS:	$-0.840

FY	2020
营收:	$211 000
毛利润:	$182 000 (86.26 %)
EPS:	$-0.624

FY	2019
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-0.430

Financial Reports:

No articles found.

Acacia Pharma Group PLC

Acacia Pharma Group plc discovers, develops, and commercializes pharmaceutical products for the patients undergoing surgery, invasive procedures, or chemotherapy treatments in the United States and internationally. The company's lead product is BARHEMSYS, an intravenous amisulpride for the treatment and prophylaxis of post-operative nausea and vomiting. Its products also include BYFAVO, an intravenous remimazolam and reversible IV sedative designed for use during invasive medical procedures, such as colonoscopy and bronchoscopy; and APD403, a selective dopamine antagonist amisulpride that has completed Phase II clinical trials for the treatment of chemotherapy-induced nausea and vomiting. Acacia Pharma Group plc was founded in 2007 and is based in Cambridge, the United Kingdom.